早期类风湿因子下降预测类风湿关节炎后续临床缓解:ANSWER队列研究
该研究基于多中心ANSWER队列1423例新启动b/tsDMARD且治疗≥12个月、基线与3个月均有RF数据的类风湿关节炎患者,回顾性分析早期RF变化与12个月CDAI缓解的关系。结果显示JAK抑制剂较TNF抑制剂带来更大幅度RF下降,早期RF下降≥20%独立关联12个月CDAI缓解(调整OR 1.39,95%CI 1.04-1.88,P=0.029),且RF下降幅度越大12个月缓解率越高(趋势P=0.004)。
要点
- JAK抑制剂较TNF抑制剂带来更大幅度早期RF下降(β=-14.50,95%CI -20.04至-8.97,P<0.001)。
- 3个月RF下降≥20%独立关联12个月CDAI缓解(调整OR 1.39,95%CI 1.04-1.88,P=0.029)。
- RF下降幅度越大,12个月缓解率越高(趋势P=0.004)。
核心结论
- 早期RF下降在不同b/tsDMARD类别间存在差异,且与12个月临床缓解独立相关。
- 纵向RF动态变化可能为RA提供有临床价值的预后信息。
研究设计与样本
- 多中心ANSWER队列回顾性分析1423例新启动b/tsDMARD治疗且持续≥12个月、基线与3个月均有RF测量的RA治疗疗程。
- 早期RF下降定义为3个月时RF较基线降低≥20%。
- 采用多变量回归评估RF变化相关因素及12个月CDAI缓解,并比较四类RF下降组的12个月缓解率。
主要发现
- RF下降在不同b/tsDMARD类别间存在差异,JAK抑制剂下降幅度最大。
- 与TNF抑制剂相比,JAK抑制剂与更大幅度RF下降相关(β=-14.50,95%CI -20.04至-8.97,P<0.001)。
- 该方向在多项敏感性分析中一致,并在倾向评分匹配分析中保持显著。
- 早期RF下降独立关联12个月CDAI缓解(调整OR 1.39,95%CI 1.04-1.88,P=0.029)。
- RF下降幅度越大的类别,12个月缓解率呈现显著总体上升趋势(趋势P=0.004)。
关键数值与推荐
- 早期RF下降定义为3个月时RF较基线降低≥20%。
- 12个月临床缓解采用CDAI评估。
- JAK抑制剂较TNF抑制剂的RF下降β=-14.50(95%CI -20.04至-8.97,P<0.001)。
- 早期RF下降与12个月CDAI缓解的调整OR=1.39(95%CI 1.04-1.88,P=0.029)。
- 四类RF下降组的12个月缓解率趋势检验P=0.004。
临床怎么用
- 对启动b/tsDMARD的RA患者,可在基线及3个月监测RF动态,早期RF下降≥20%提示12个月CDAI缓解可能性更高。
- JAK抑制剂较TNF抑制剂带来更大幅度早期RF下降,但选择药物仍需综合患者情况。
局限性
- 本研究为回顾性队列分析,存在残余混杂可能。
- 早期RF下降定义为3个月较基线降低≥20%,其他阈值未评估。
- 研究基于ANSWER队列,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare early changes in RF across classes of biological or targeted synthetic DMARDs (b/tsDMARDs) and assess whether early RF decline was associated with 12-month clinical remission in RA. METHODS: We retrospectively analysed 1423 newly initiated b/tsDMARD treatment courses from the multicentre ANSWER cohort that continued for ≥12 months and had RF measured at baseline and 3 months. Early RF decline was defined as a ≥20% reduction at 3 months. Multivariable regression assessed factors associated with RF change and 12-month Clinical Disease Activity Index (CDAI) remission. Twelve-month remission rates were also compared across four categories of RF reduction. RESULTS: RF reduction differed across classes, with Janus kinase inhibitors (JAKi) showing the greatest decline. Compared with TNF inhibitors (TNFi), JAKi were associated with a greater RF reduction (β = -14.50, 95% CI: -20.04 to -8.97; P < 0.001). The direction was similar in multiple sensitivity analyses and remained significant in propensity score-matched analyses. Early RF decline was independently associated with 12-month CDAI remission (adjusted OR 1.39, 95% CI: 1.04-1.88; P = 0.029). A significant overall trend towards higher 12-month remission rates was observed across categories of greater RF reduction (P for trend = 0.004). CONCLUSION: Early RF decline differed across b/tsDMARD classes and was associated with 12-month remission. Longitudinal RF dynamics may provide clinically useful prognostic information in RA.
引用
- Sugimoto K, Watanabe R, Fujita Y, et al. Early rheumatoid factor decline predicts subsequent clinical remission in rheumatoid arthritis: the ANSWER cohort. Rheumatology (Oxford). 2026. PMID: 42714931. doi:10.1093/rheumatology/keag498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。